16 completed. 16 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 16 |
| Phase 2 | 4 | Completed 4 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects STSA-1002 subcutaneous injection - Antineutrophil Cytoplasmic Antibody Associated Vasculitis | Phase 1 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 20 | 2023-01-31 | 2023-05-26 |
| Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 93 | 2022-02-22 | 2025-08-07 |
| A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants Avacopan, Moxifloxacin, Placebo for avacopan - Electrocardiography | Phase 1 | Completed | Amgen | 58 | 2019-11-08 | 2023-08-14 |
| A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment Avacopan - Hepatic Impairment | Phase 1 | Completed | Amgen | 24 | 2018-04-17 | 2023-08-22 |
| A Study of CCX168 in Japanese and Caucasian Healthy Adult Males CCX168, Placebo - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 | Completed | Amgen | 80 | 2017-10-23 | 2023-08-14 |
| A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications CCX168, Midazolam, Celecoxib - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 | Completed | Amgen | 32 | 2016-01-14 | 2023-08-22 |
| A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168 CCX168 - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 | Completed | Amgen | 16 | 2015-12-03 | 2023-08-14 |
| A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants [14C]CCX168 - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 | Completed | Amgen | 6 | 2014-10-20 | 2023-08-22 |
| Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis Abatacept - Wegener's Granulomatosis | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 20 | 2008-02-01 | 2016-01-18 |
| Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Mepolizumab - Churg Strauss Syndrome | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 10 | 2007-09-01 | 2017-03-22 |
| An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Rituximab - Wegener's Granulomatosis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2003-10-01 | 2008-03-04 |
| CellCept in p-ANCA Vasculitis CellCept (mycophenolate mofetil) - MPO-ANCA Vasculitis, Microscopic Polyangiitis | Phase 1 | Completed | Mayo Clinic | 18 | 2002-12-01 | 2011-03-23 |
| Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Mepolizumab - Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 24 | 2001-12-01 | 2020-07-29 |
| Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions Mycophenolate Mofetil - Vasculitis, Wegener's Granulomatosis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 1998-04-01 | 2008-03-04 |
| Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis Interleukin-10 - Vasculitis, Wegener's Granulomatosis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 1998-02-01 | 2008-03-04 |
| Diagnostic Effectiveness of Virtual Bronchoscopy virtual bronchoscopy - Bronchogenic Carcinoma, Chronic Granulomatous Disease | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 120 | 1995-12-01 | 2008-03-04 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8) · Vasculitis (8) · Granulomatosis with Polyangiitis (5) · Vascular Diseases (3) · Cardiovascular Diseases (2) · Churg-Strauss Syndrome (2) · Atypical Hemolytic Uremic Syndrome (1) · Autoimmune Diseases (1) · Carcinoma, Bronchogenic (1) · Eosinophilic Esophagitis (1) · Eosinophilic enteropathy (1) · Glomerulonephritis, IGA (1) · Granulomatous Disease, Chronic (1) · Hypereosinophilic Syndrome (1) · Inflammation (1)
Immune System Diseases (16) · Skin Diseases (16) · Skin Diseases, Vascular (16) · Skin and Connective Tissue Diseases (16) · Autoimmune Diseases (15) · Cardiovascular Diseases (14) · Vascular Diseases (13) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8) · Vasculitis (8) · Lung Diseases (5) · Lung Diseases, Interstitial (5) · Respiratory Tract Diseases (5) · Hemic and Lymphatic Diseases (4) · Hematologic Diseases (3)
avacopan (5) · Mycophenolic Acid (2) · mepolizumab (2) · Abatacept (1) · BDB001 (1) · Celecoxib (1) · Cyclophosphamide (1) · Glucocorticoids (1) · Interleukin-10 (1) · Itraconazole (1) · Midazolam (1) · Moxifloxacin (1) · Prednisone (1) · Rifampin (1) · Rituximab (1)
Amgen (6) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (2) · Brigham and Women's Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · Mayo Clinic (1) · National Institutes of Health Clinical Center (CC) (1) · University of Pennsylvania (1)
United States (14) · China (1) · Japan (1)
Carol A. Langford, MD, MHS (1) · Fernando C. Fervenza, M.D., Ph.D. (1) · Marc E. Rothenberg, MD (1) · Martin K Kankam, Doctor (1) · Michael Wechsler, MD (1) · Minghui Zhao, Postdoc (1) · Peter A. Merkel, MD, MPH (1)
PMID 20093349, PMID 24323392, PMID 38973157, PMID 38993026
U54AR057319 (1)